Cargando…

Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO

We have studied the long-term toxicity of a Roundup-tolerant GM maize (NK603) and a whole Roundup pesticide formulation at environmentally relevant levels from 0.1 ppb. Our study was first published in Food and Chemical Toxicology (FCT) on 19 September, 2012. The first wave of criticisms arrived wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Séralini, Gilles-Eric, Mesnage, Robin, Defarge, Nicolas, Spiroux de Vendômois, Joël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044951/
https://www.ncbi.nlm.nih.gov/pubmed/27752411
http://dx.doi.org/10.1186/s12302-014-0013-6
_version_ 1782457026680455168
author Séralini, Gilles-Eric
Mesnage, Robin
Defarge, Nicolas
Spiroux de Vendômois, Joël
author_facet Séralini, Gilles-Eric
Mesnage, Robin
Defarge, Nicolas
Spiroux de Vendômois, Joël
author_sort Séralini, Gilles-Eric
collection PubMed
description We have studied the long-term toxicity of a Roundup-tolerant GM maize (NK603) and a whole Roundup pesticide formulation at environmentally relevant levels from 0.1 ppb. Our study was first published in Food and Chemical Toxicology (FCT) on 19 September, 2012. The first wave of criticisms arrived within a week, mostly from plant biologists without experience in toxicology. We answered all these criticisms. The debate then encompassed scientific arguments and a wave of ad hominem and potentially libellous comments appeared in different journals by authors having serious yet undisclosed conflicts of interests. At the same time, FCT acquired as its new assistant editor for biotechnology a former employee of Monsanto after he sent a letter to FCT to complain about our study. This is in particular why FCT asked for a post-hoc analysis of our raw data. On 19 November, 2013, the editor-in-chief requested the retraction of our study while recognizing that the data were not incorrect and that there was no misconduct and no fraud or intentional misinterpretation in our complete raw data - an unusual or even unprecedented action in scientific publishing. The editor argued that no conclusions could be drawn because we studied 10 rats per group over 2 years, because they were Sprague Dawley rats, and because the data were inconclusive on cancer. Yet this was known at the time of submission of our study. Our study was however never attended to be a carcinogenicity study. We never used the word ‘cancer’ in our paper. The present opinion is a summary of the debate resulting in this retraction, as it is a historic example of conflicts of interest in the scientific assessments of products commercialized worldwide. We also show that the decision to retract cannot be rationalized on any discernible scientific or ethical grounds. Censorship of research into health risks undermines the value and the credibility of science; thus, we republish our paper.
format Online
Article
Text
id pubmed-5044951
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-50449512016-10-15 Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO Séralini, Gilles-Eric Mesnage, Robin Defarge, Nicolas Spiroux de Vendômois, Joël Environ Sci Eur Commentary We have studied the long-term toxicity of a Roundup-tolerant GM maize (NK603) and a whole Roundup pesticide formulation at environmentally relevant levels from 0.1 ppb. Our study was first published in Food and Chemical Toxicology (FCT) on 19 September, 2012. The first wave of criticisms arrived within a week, mostly from plant biologists without experience in toxicology. We answered all these criticisms. The debate then encompassed scientific arguments and a wave of ad hominem and potentially libellous comments appeared in different journals by authors having serious yet undisclosed conflicts of interests. At the same time, FCT acquired as its new assistant editor for biotechnology a former employee of Monsanto after he sent a letter to FCT to complain about our study. This is in particular why FCT asked for a post-hoc analysis of our raw data. On 19 November, 2013, the editor-in-chief requested the retraction of our study while recognizing that the data were not incorrect and that there was no misconduct and no fraud or intentional misinterpretation in our complete raw data - an unusual or even unprecedented action in scientific publishing. The editor argued that no conclusions could be drawn because we studied 10 rats per group over 2 years, because they were Sprague Dawley rats, and because the data were inconclusive on cancer. Yet this was known at the time of submission of our study. Our study was however never attended to be a carcinogenicity study. We never used the word ‘cancer’ in our paper. The present opinion is a summary of the debate resulting in this retraction, as it is a historic example of conflicts of interest in the scientific assessments of products commercialized worldwide. We also show that the decision to retract cannot be rationalized on any discernible scientific or ethical grounds. Censorship of research into health risks undermines the value and the credibility of science; thus, we republish our paper. Springer Berlin Heidelberg 2014-06-24 2014 /pmc/articles/PMC5044951/ /pubmed/27752411 http://dx.doi.org/10.1186/s12302-014-0013-6 Text en © Séralini et al.; licensee Springer 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Séralini, Gilles-Eric
Mesnage, Robin
Defarge, Nicolas
Spiroux de Vendômois, Joël
Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO
title Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO
title_full Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO
title_fullStr Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO
title_full_unstemmed Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO
title_short Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO
title_sort conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a gmo
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044951/
https://www.ncbi.nlm.nih.gov/pubmed/27752411
http://dx.doi.org/10.1186/s12302-014-0013-6
work_keys_str_mv AT seralinigilleseric conflictsofinterestsconfidentialityandcensorshipinhealthriskassessmenttheexampleofanherbicideandagmo
AT mesnagerobin conflictsofinterestsconfidentialityandcensorshipinhealthriskassessmenttheexampleofanherbicideandagmo
AT defargenicolas conflictsofinterestsconfidentialityandcensorshipinhealthriskassessmenttheexampleofanherbicideandagmo
AT spirouxdevendomoisjoel conflictsofinterestsconfidentialityandcensorshipinhealthriskassessmenttheexampleofanherbicideandagmo